M. J. BOND, L. CHU, D. A. NALAWANSHA, K. LI, C. M. CREWS* (YALE UNIVERSITY, NEW HAVEN, USA)
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
ACS Cent. Sci. 2020, 6, 1367-1375, DOI: 10.1021/acscentsci.0c00411.

## A PROTAC for KRAS G12C Degradation



Significance: KRas is one of the most promising cancer drug targets, but targeting it has been a challenge. Crews and co-workers employed covalent KRas G12C inhibitors for the development of PROTACS that allowed for its targeted degradation.

Comment: A solvent-exposed site in the clinical drug candidate MRTX849 was identified and used for conjugation to a linker and a VHL ligand to yield the PROTAC LC-2.

## Category

Chemistry in Medicine and Biology

## Key words

## KRAS

targeted
degradation

## cancer

drug development


